Equity Incentive Plan (Tables)

3 Months Ended

Mar. 31, 2023

Schedule of Additional Information on Stock Option Grants And Vesting

The following table summarizes additional information on stock option grants and vesting (in thousands):

	2019 Plan
	Three Months Ended March 31, 2023		Three Months Ended March 31, 2022
Total fair value of stock options granted	$	—	$	2,884
Total fair value of options vested		1,465		609

Schedule of Black Scholes model for the Private Warrants

The Company did not grant any time or performance-based vesting stock options during the three

months ended March 31, 2023. The following table summarizes the assumptions used in the valuation models to determine the fair value of awards granted to employees and non-employee directors under the 2019 Plan:

	Three Months Ended March 31, 2022
Expected volatility		42.90	%
Expected term (in years)	6.00
Dividend yield		0.00	%
Risk-free interest rate		1.62	%

Stock Based Compensation Expense Included In Condensed Consolidated Statements of Comprehensive Loss

Stock-based compensation expense is included in the Company’s Condensed Consolidated Statements of Comprehensive Loss within the following line items (in thousands):

	Three Months Ended March 31, 2023		Three Months Ended March 31, 2022
Cost of revenues	$	227	$	351
General and administrative		443		408
Research and development		76		103
Sales and marketing		87		200
Total	$	833	$	1,062

Restricted Stock Units [Member]

Schedule of RSUs Activity Under 2019 Plan

The following table summarizes the Company’s RSU activity for performance based RSUs awarded to employees and for time-based RSUs granted to non-employee directors under the 2019 Plan:

Description	RSUs Outstanding
Outstanding at December 31, 2022		1,876,669
Granted		151,515
Vested - non-employee director awards		(16,667	)
Forfeited		(19,289	)
Expired		—
Outstanding at March 31, 2023		1,992,228

2019 Plan [Member]

Schedule of Stock Option Activity Under 2019 Plan

The following table summarizes the Company’s stock option activity under the 2019 Plan:

Description	Options Outstanding			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value (1)
Options outstanding, December 31, 2022		5,757,779		$	7.92		7.6	$	—
Granted		—			—
Exercised		—			—
Forfeited		(9,451	)		7.34
Expired		(75,714	)		8.12
Options outstanding, March 31, 2023		5,672,614		$	7.91		7.4	$	—
Options vested and exercisable, March 31, 2023		4,428,571		$	8.16		7.1	$	—
Options vested and expected to vest, March 31, 2023		5,672,614		$	7.91		7.4	$	—

_______________________________

(1)Aggregate intrinsic value (in thousands) represents the difference between the estimated fair value of the underlying Common Stock and the exercise price of outstanding in-the-money options.